Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells
2010
Eadie, L. | Hughes, T. | White, D.
L. Eadie, T. P. Hughes and D. L. White
Показать больше [+] Меньше [-]Ключевые слова АГРОВОК
Библиографическая информация
Издатель
Nature Publishing Group
Другие темы
Chronic; Octamer transcription factor-1; Bcr-abl positive; Tetraethylammonium; Tumor cells; Prazosin; Protein kinase inhibitors; Benzamides; Imatinib mesylate; Adrenergic alpha-antagonists; Cultured; Combination; Myelogenous; Protein-tyrosine kinases
Язык
Английский
Лицензия
© 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.
ISSN
0887-6924, 1476-5551, 0000-0003, 1912-7602, 0000-0002, 0910-3730, 7990-4509, 4844-333X
Тип
Journal Article; Journal Part
Источник
https://doi.org/10.1038/leu.2010.7
2024-10-18
2025-10-25
Dublin Core
Поставщик данных
Эту запись предоставил University of Adelaide
If you notice any incorrect information relating to this record, please contact us at [email protected] [email protected]